# A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia

> **NCT02326454** · PHASE2 · COMPLETED · sponsor: **Light Sciences Oncology** · enrollment: 225 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** talaporfin sodium
- **DRUG:** Saline
- **DEVICE:** Drug Activator 100 J/cm
- **DEVICE:** Drug Activator 200 J/cm

## Key facts

- **NCT ID:** NCT02326454
- **Lead sponsor:** Light Sciences Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-03-29
- **Final completion:** 2017-03-29
- **Target enrollment:** 225 (ACTUAL)
- **Last updated:** 2018-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02326454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02326454, "A Placebo Controlled Study of MR901 (Talaporfin Sodium Sodium + a Drug-activating Device) for the Relief of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02326454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*